



Issued: 22 August 2011

Melbourne, Australia

GSK Awarded Funds to Advance Dermal Treatment with Starpharma's Dendrimers

GlaxoSmithKline (GSK), and Starpharma (ASX:SPL, OTCQX:SPHY) today announced that GSK was awarded a grant to advance a dermal treatment based on Starpharma's dendrimer drug delivery technology.

The funds will be used to support Starpharma's synthesis of dendrimer-based drug candidates which will then be tested by Stiefel, a GSK company with a view to further development towards a dermal product.

The funding has been provided under a grant program run by the Victorian Government.

Dr Jackie Fairley, CEO Starpharma said "We are very pleased to have this opportunity to further develop our valued relationship with GSK through their dermatology business Stiefel. We remain extremely upbeat about the value of dendrimers for a wide range of drug delivery applications and look forward to working with Stiefel to apply our technology to dermal applications."

Ms Deborah Waterhouse, General Manager GSK Aus & NZ said "The partnership with Starpharma is an exciting step forward for Stiefel, which is committed to innovation in dermatology leading to new medicines for patients."

Starpharma's dendrimers are a type of precisely-defined, branched nanoparticle. In pharmaceuticals dendrimers have applications in enhancing drug half-life, solubilising drugs, and targeting drugs to specific destinations in the body. More widely dendrimers have applications in medical, electronics, chemicals and materials industries.

ends.

Enquiries:

Starpharma

Dr Jackie Fairley, Chief Executive Officer: Tel +61 3 8532 2704

Ben Rogers, Company Secretary: Tel +61 3 8532 2704 ben.rogers@starpharma.com

Media: Rebecca Wilson: Buchan Consulting Tel: +61 417 382 391 rwilson@bcg.com.au

Lisa Maguire: GlaxoSmithKline

Tel: + 61 3 9721 6637 Fax: + 61 3 8761 2442 Mobile: 0449 950 745



<More>

About GSK

GlaxoSmithKline is a global research-based pharmaceutical and healthcare company with a proud history in Australia dating back to 1886. We collaborate with local researchers and doctors to discover new ways of treating and preventing disease, investing around \$45.2 million a year in research and development. We are pioneering new treatments for complex diseases like cancer, and we are leaders in vaccine technology and the treatment of respiratory disease, anti-virals, central nervous system and diabetes. We currently have over 30 discovery projects underway and our Medicines Research Unit is the only Phase 1 facility supported by a pharmaceutical company in Australia. Stiefel, a GSK company, specialises in dermatology.

About Stiefel, a GSK company

Stiefel, a GSK company, is committed to advancing dermatology and skin science around the world in order to help people better achieve healthier skin. Stiefel's dedication to innovation, along with its focus on pharmaceutical, over-the-counter and aesthetic dermatology products, has established Stiefel as a world leader in the skin health industry. To learn more about Stiefel, visit www.stiefel.com.

About Starpharma

Starpharma Holdings Limited (ASX:SPL, OTCQX:SPHY) is a world leader in the development of dendrimer technology for pharmaceutical, life-science and other applications. SPL has two operating companies, Starpharma Pty Ltd in Melbourne, Australia and DNT, Inc in the USA. Products based on SPL's dendrimer technology are already on the market in the form of diagnostic elements and laboratory reagents through licence arrangements with partners including Siemens and Merck KgA.

The Company's lead pharmaceutical development product is VivaGel[®] (SPL7013 Gel), a vaginal microbicide designed to prevent the transmission of STIs, including HIV and genital herpes. Starpharma has a licence agreement with Ansell Limited to develop a VivaGel[®]-coated condom, and a licence agreement with Okamoto Industries Inc in relation to the VivaGel[®]-coated condom for the Japanese market. Okamoto is the market leader for condoms sold in Japan, the world's second largest condom market.

Starpharma also has agreements in place with Lilly, Elanco, Stiefel, a GSK Company, and Siemens Healthcare as well as many research collaborations with some of the world's leading organisations in the fields of pharmaceuticals, drug delivery, cosmetics and agrochemicals.

American Depositary Receipts (ADRs): Starpharma's ADRs trade under the code **SPHY** (CUSIP number 855563102). Each Starpharma ADR is equivalent to 10 ordinary shares of Starpharma as traded on the Australian Securities Exchange (ASX). Starpharma's ADRs are listed on International OTCQX, a premium market tier in the U.S. for international exchange-listed companies, operated by OTC Markets Group Inc. (www.otcm Markets.com).

Forward Looking Statements

This document contains certain forward-looking statements, relating to Starpharma's business, which can be identified by the use of forward-looking terminology such as "promising", "plans", "anticipated", "will", "project", "believe", "forecast", "expected", "estimated", "targeting", "aiming", "set to", "potential", "seeking to", "goal", "could provide", "intends", "is being developed", "could be", "on track", or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA's and other health authorities' requirements regarding any one or more product candidates nor can there be any assurance that such product candidates will be approved by any health authorities for sale in any market or that they will reach any particular level of sales. In particular, management's



expectations regarding the approval and commercialization of the product candidates could be affected by, among other things, unexpected clinical trial results, including additional analysis of existing clinical data, and new clinical data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. Starpharma is providing this information as of the date of this document and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise.